BCIQ Profiles

Company Profile ReportTarget Profile Report

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme A metabolism.

Comet Therapeutics Inc. (Cambridge, Mass.) has its roots

Read the full 449 word article

How to gain access

Continue reading with a
two-week free trial.